The CLEC2B (C-type lectin domain family 2 member B) antibody is a research tool targeting the CLEC2B protein, a member of the C-type lectin receptor (CLR) family involved in immune regulation and cellular interactions. CLEC2B, also known as activation-induced C-type lectin (AICL), is encoded by the *CLEC2B* gene and expressed on myeloid cells, platelets, and certain lymphocytes. It functions as a transmembrane receptor capable of modulating immune responses through interactions with endogenous or exogenous ligands. Structurally, CLEC2B contains a single extracellular C-type lectin-like domain, a stalk region, and a cytoplasmic tail lacking canonical signaling motifs, suggesting reliance on adaptor proteins for signal transduction. Studies link CLEC2B to inflammatory processes, platelet activation, and immune evasion in cancers. Antibodies against CLEC2B are used to investigate its role in diseases like rheumatoid arthritis, leukemia, and viral infections (e.g., HIV), where CLEC2B may influence pathogen recognition or immune cell communication. These antibodies enable detection of CLEC2B expression in tissues or cells via techniques such as flow cytometry, immunohistochemistry, and Western blot. Recent research also explores CLEC2B's interaction with ligands like heparan sulfate proteoglycans and its potential as a therapeutic target. However, its precise biological functions and signaling mechanisms remain under investigation, highlighting the importance of CLEC2B-specific antibodies in advancing mechanistic and translational studies.